How to Monitor Kidney Function: Blood, Urine & Imaging

Kidney function is tracked through a layered set of tools, starting with routine blood and urine tests and escalating to imaging and sometimes tissue biopsy when the clinical picture demands it. No single test tells the whole story. A blood draw can estimate how well your kidneys filter waste, a urine sample can reveal whether protein is leaking through damaged filters, and imaging can show whether the kidneys are structurally normal. How these tools are combined, and how often they are repeated, depends on whether your doctor is screening for early trouble, managing established kidney disease, or investigating a sudden change.

The Blood Test You Will Get First

Almost every kidney check starts with a serum creatinine level. Creatinine is a waste product of normal muscle metabolism, and healthy kidneys clear it from your blood at a predictable rate. When kidney function drops, creatinine accumulates. Rather than interpreting the raw creatinine number in isolation, laboratories plug it into an equation that estimates your glomerular filtration rate, the volume of blood your kidneys filter per minute. This estimated GFR (eGFR) is the number your doctor actually uses to stage kidney disease and make treatment decisions.

The equations are imperfect. A systematic review and meta-analysis of creatinine-based eGFR equations in the United States found a mean bias of roughly 1 to 2 mL/min per 1.73 m² across racial subgroups, but individual-study results ranged from overestimating true GFR by 9 mL/min to underestimating it by more than 12 mL/min.¹ That spread matters: a few points of error can push someone into a different kidney disease stage, potentially changing drug dosing or transplant eligibility.

Why Creatinine Alone Can Mislead You

Creatinine is a proxy, and proxies have blind spots. Your creatinine level reflects not just kidney filtration but also how much muscle you carry, how much meat you eat, and how physically active you are. In one study, people who exercised at moderate to high intensity had significantly higher serum creatinine than sedentary people, largely because they had more lean mass, not because their kidneys were worse.² That same study found that cystatin C, an alternative blood marker, was not affected by lean mass in the same way. Age, diet, pregnancy, and critical illness can also shift creatinine independently of actual kidney function.³

This is especially relevant at the extremes of body composition. A frail elderly person with very little muscle mass may have a “normal” creatinine level even when their kidneys are failing, because they simply do not produce much creatinine to begin with. Conversely, a young bodybuilder might trigger a low eGFR that is really just an artifact of high muscle turnover.

Cystatin C and the Combined Equation

Cystatin C is produced by nearly all cells in the body at a relatively steady rate, making it less dependent on muscle mass than creatinine. A large study across diverse populations found that using cystatin C alone, or combining it with creatinine, strengthened the link between eGFR and the risks of death and kidney failure compared with creatinine alone.⁴ In practice, many guidelines now recommend a combined creatinine-cystatin C equation when the creatinine-based estimate seems unreliable or when a more precise number is needed for clinical decisions like transplant evaluation.

Body weight introduces its own wrinkles. In a Northern European population study, creatinine-based eGFR overestimated true kidney function in people with a BMI under 20 or above 30, while cystatin C-based eGFR underestimated it in people with obesity. The combined creatinine-cystatin C equation had the least bias and the best classification accuracy across all BMI categories.⁵ If you are significantly under- or overweight and your doctor is relying on creatinine alone, you might want to ask about adding cystatin C.

Blood Urea Nitrogen and Its Limits

Blood urea nitrogen, or BUN, is another waste product measured on standard blood panels. Doctors have traditionally looked at the ratio of BUN to creatinine to help distinguish between kidney problems caused by dehydration or low blood flow (prerenal causes) and those caused by direct kidney damage. The idea was that a high ratio pointed to a flow problem, while a normal ratio pointed to structural damage.

The evidence for this distinction is weak. One hospital-based study found that roughly half of patients with acute kidney injury had a BUN-to-creatinine ratio above the traditional threshold, but the ratio did not follow the neat two-group pattern clinicians expected. The relationship between the ratio and mortality was J-shaped, and patients with the pattern traditionally linked to “reversible” dehydration-type injury actually had higher mortality than those with lower ratios.⁶ A separate emergency-department study confirmed this, finding no statistical difference in the ratio between prerenal and intrinsic acute kidney injury groups, with the ratio showing no ability to discriminate between the two.⁷ BUN still has clinical uses, but its role in sorting out why the kidneys are struggling is not as clear-cut as textbooks once taught.

What Urine Tests Add

Blood tests estimate how well the kidneys filter, but urine tests reveal what is slipping through the filter that should not be. Protein in the urine, particularly albumin, is one of the earliest signs of kidney damage. It often appears years before eGFR starts to drop, which is why screening guidelines focus on it for people with diabetes and high blood pressure.

The gold standard for quantifying protein loss is a 24-hour urine collection, where you save every drop of urine for a full day and the lab measures total protein output. This is accurate but deeply inconvenient. The spot urine protein-to-creatinine ratio (UPCR) offers a faster alternative: a single urine sample is tested, and the protein concentration is divided by the creatinine concentration to approximate what a full-day collection would show. One study found a correlation of 0.92 between the spot ratio and 24-hour protein excretion.⁸ In a cancer treatment trial, using a UPCR cutoff to screen patients would have reduced the need for 24-hour collections by about three-quarters while missing less than 1% of significant proteinuria.⁹

The spot ratio is not perfect for every kidney disease. In patients with IgA nephropathy, the correlation between spot UPCR and 24-hour collection remained strong. But in patients with membranous nephropathy with nephrotic syndrome, the correlation broke down and was not statistically significant.¹⁰ For conditions with heavy or fluctuating protein loss, the 24-hour collection may still be necessary.

Dipstick Versus Lab-Measured Albumin

The simplest urine test is the dipstick, a chemically treated strip dipped into a urine sample that changes color to indicate protein. It is cheap, fast, and available almost everywhere. But cheapness has a trade-off. A population-based study comparing the dipstick to the albumin-to-creatinine ratio (ACR) found that the dipstick had a sensitivity of only about 44% for detecting clinically meaningful albuminuria, meaning it missed more than half of affected individuals.¹¹ Specificity was high, so a positive dipstick result is usually real, but a negative one does not rule out early kidney damage.

Even using multiple dipstick readings over time does not fully close the gap. A study of non-diabetic patients found that combining three dipstick measurements still had lower sensitivity for detecting microalbuminuria than a single protein-to-creatinine ratio measurement.¹² If you are being screened for early kidney disease, a lab-measured ACR or UPCR is more reliable than dipstick testing alone.

Ultrasound and Basic Kidney Imaging

Blood and urine tests measure function, but they cannot show you the physical state of the kidney. That is where imaging comes in. Ultrasound is usually the first imaging tool ordered because it is radiation-free, widely available, and relatively inexpensive. It shows kidney size, shape, and whether there are structural problems like cysts, stones, or obstructions blocking urine flow.

Kidney length, cortical thickness, and echogenicity (how bright the kidney tissue appears on the screen) all carry diagnostic information. One study found that combining kidney length with cortical echogenicity improved the ability to predict both low eGFR and abnormal findings on tissue biopsy, compared to using kidney length or cortical thickness alone.¹³ In acute kidney injury, ultrasound helps clinicians assess size, echogenicity, the renal hilum, and blood-vessel flow patterns as part of a structured evaluation.¹⁴

Doppler ultrasound adds another dimension by measuring blood flow within the kidney. The renal resistive index, derived from Doppler readings, has been used to evaluate transplant rejection, detect renal artery narrowing, assess the progression risk of chronic kidney disease, and predict outcomes in critically ill patients. Research also suggests that an elevated resistive index reflects not just local kidney changes but systemic vascular stiffness, making it potentially useful in managing hypertension.¹⁵

CT, MRI, and the Contrast Agent Question

When ultrasound is not enough, CT and MRI scans provide more detailed images of kidney structure and surrounding anatomy. CT is fast and excellent for detecting stones, tumors, and vascular abnormalities. MRI can characterize soft tissue with greater precision. Both often require contrast agents to highlight blood vessels and tissue differences, and this is where kidney patients face a specific dilemma.

Iodinated contrast used in CT scans can cause contrast-induced nephropathy, an acute decline in kidney function defined by a rise in serum creatinine after the contrast is administered. People with moderate to severe chronic kidney disease are at the highest risk.¹⁶ Gadolinium-based contrast used in MRI carries a different risk: nephrogenic systemic fibrosis (NSF), a rare but serious condition in which connective tissue forms in the skin and organs. Patients with end-stage kidney disease, acute kidney injury, or stage 4–5 chronic kidney disease face the highest risk of NSF, particularly with certain types of gadolinium agents.¹⁷

In patients with kidney impairment, low clearance of the gadolinium-carrier complex, combined with acid-base imbalances and high phosphorus levels, can increase the release of free gadolinium into tissues, raising the risk of toxicity.¹⁸ Modern guidelines have reduced the occurrence of NSF dramatically by restricting the highest-risk gadolinium agents in people with severely reduced kidney function and by screening eGFR before ordering contrast-enhanced MRI. If you have known kidney disease and are told you need a contrast scan, your doctor should check your eGFR beforehand and weigh the diagnostic benefit against the contrast risk.

Nuclear Scans for Split Kidney Function

Standard blood tests give you a single eGFR number that represents the combined output of both kidneys. When doctors need to know how much each kidney contributes individually — before removing a kidney for donation, for instance, or when one kidney is blocked — they turn to nuclear medicine scans. These inject a small amount of a radioactive tracer and use a gamma camera to watch how each kidney takes up and clears the tracer.

The most common tracers are DMSA, DTPA, and MAG3, each suited to slightly different clinical questions. DMSA binds to the kidney cortex and excels at detecting scars and measuring relative function. DTPA and MAG3 are filtered and excreted, so they also show drainage patterns. A comparison study found very high correlation between DMSA and the dynamic tracers for measuring the split between the two kidneys, with the average difference between DMSA and MAG3 measurements being negligible.¹⁹

Measuring True GFR When Estimates Are Not Enough

Sometimes the stakes are high enough that an estimate will not do. Measured GFR, determined by injecting a marker like iohexol into the bloodstream and tracking how quickly the kidneys clear it, is the reference standard. A pooled analysis of iohexol clearance studies found it agreed with the traditional inulin-clearance gold standard to within 30% in about 86% of cases, with a median bias of only 3%.²⁰ This procedure involves timed blood draws over several hours, so it is reserved for situations where precision truly matters: living kidney donor evaluation, drug dosing in clinical trials, and resolving ambiguous eGFR results.

Tracking Kidney Function Over Time

A single eGFR snapshot tells you where you are, but the trajectory tells you where you are headed. The rate at which eGFR declines over time, called the eGFR slope, is increasingly recognized as one of the most informative metrics in kidney disease management. A large meta-analysis found that the treatment effect on eGFR slope was almost perfectly correlated with the treatment effect on actual kidney failure across clinical trials, supporting its use as a primary endpoint for judging whether a therapy is working.²¹

The clinical meaning of the slope depends on where you start. In a Japanese cohort study, slowing the eGFR decline by about 1.9 mL/min per year in stage 3 CKD was associated with a 20% lower risk of eventually needing dialysis or transplant. In stages 4 and 5, a much smaller deceleration of about 1.1 and 1.1 mL/min per year carried the same relative risk reduction, because patients closer to kidney failure have less margin to lose.²² If your nephrologist tracks your eGFR across visits and talks about the slope, they are using one of the best available predictors of your long-term outcome.

Emerging Blood Biomarkers for Acute Injury

Creatinine is sluggish. After an acute kidney injury event, creatinine may not rise noticeably for 24 to 48 hours, delaying diagnosis. Researchers have been searching for biomarkers that flag kidney damage earlier. In a Chinese emergency-department study of patients with sepsis, several markers — cystatin C, KIM-1 (kidney injury molecule-1), NGAL (neutrophil gelatinase-associated lipocalin), and FGF-23 — were all significantly elevated at admission in patients who went on to develop acute kidney injury compared with those who did not.²³ These markers are not yet part of standard care everywhere, but NGAL and KIM-1 in particular are moving toward clinical use in intensive care settings where catching kidney injury hours earlier could change management.

Monitoring Transplanted Kidneys

After a kidney transplant, detecting rejection early is critical for saving the graft. The traditional approach relies on serial creatinine checks and periodic biopsies, but biopsies are invasive and sample only a tiny piece of the organ. Donor-derived cell-free DNA (dd-cfDNA) offers a blood-based alternative. When transplant cells are injured, they release fragments of the donor’s DNA into the recipient’s bloodstream, and this can be measured with a simple blood draw.

A large study found that dd-cfDNA levels strongly correlated with antibody-mediated, T cell-mediated, and mixed rejection, and that adding dd-cfDNA to standard monitoring improved the ability to detect rejection beyond what creatinine and other routine tests could achieve alone.²⁴ Earlier work established practical thresholds: dd-cfDNA levels below 1% indicated the absence of active rejection with a negative predictive value of 84%, while levels above 1% flagged the probability of active rejection.²⁵ The test has also been validated in pediatric transplant recipients, where dd-cfDNA was independently associated with rejection and improved discrimination when added to standard monitoring.²⁶

dd-cfDNA does not replace biopsy entirely — a biopsy still provides the definitive tissue diagnosis and guides specific treatment decisions.²⁷ But it may reduce the number of biopsies needed by identifying patients who are unlikely to be rejecting, and by triggering earlier biopsy in those whose dd-cfDNA rises before creatinine does.

At-Home and Point-of-Care Testing

For people living with kidney disease or a transplant, frequent clinic visits for blood draws are a real burden. At-home creatinine monitoring is starting to become feasible. A clinical study of kidney transplant recipients found that self-testing with a handheld point-of-care device at home produced creatinine results with strong clinical agreement to standard laboratory venous blood testing, with all 40 paired results falling within acceptable ranges.²⁸

Researchers are also developing smartphone-connected biosensors that could bring creatinine testing even closer to a home glucose monitor. One prototype used photochemical detection of whole blood creatinine and showed strong correlation with standard laboratory analyzers across 43 clinical samples, with Bluetooth capability for transmitting results to a phone-based app.²⁹ These are still in development, but the direction is clear: kidney monitoring is moving from something that happens only in a clinic to something you can do between visits.

Transdermal GFR Measurement

Perhaps the most striking emerging approach skips the blood draw entirely. Transdermal GFR measurement uses a fluorescent tracer injected into the bloodstream and a sensor worn on the skin that tracks how quickly the tracer is cleared. A recent accuracy study found that this method agreed with standard measured GFR to within 30% in 94% of cases, meeting its prespecified accuracy threshold.³⁰ Unlike iohexol clearance, which requires multiple timed blood draws, the transdermal approach collects data passively through the skin. If validated in larger trials, it could make measured GFR far more accessible, turning what is currently a specialized procedure into something closer to a routine office test.

Kidney Function in Children

Monitoring kidney function in children and newborns presents unique challenges. Children have lower muscle mass relative to body size, and neonatal kidney function changes rapidly in the first weeks of life as the kidneys mature. The adult eGFR equations do not work well in this population. Several pediatric-specific formulas have been developed using various combinations of creatinine, cystatin C, and body measurements like height, and the choice of equation matters for accurate staging and drug dosing.³¹ If your child’s kidney function is being monitored, the lab should be using a pediatric formula rather than the standard adult equation.